MedPath

DMEK Versus DSAEK Study

Not Applicable
Completed
Conditions
Fuchs' Endothelial Dystrophy
Interventions
Procedure: DMEK
Procedure: DSAEK
Registration Number
NCT02793310
Lead Sponsor
Maastricht University Medical Center
Brief Summary

The purpose of this study is to determine whether corneal transplantation by Descemet Membrane Endothelial Keratoplasty more favourable and cost-effective is compared to Descemet Stripping Automated Endothelial Keratoplasty for Fuchs Endothelium Corneal Dystrophy.

Detailed Description

FECD is a progressive, multifactorial and irreversible disease characterized by accelerated loss of corneal endothelial cells in the innermost layer of the cornea that leads to vision impairment and potential blindness if left untreated. FECD is responsible for more than 50% of the 1.300 annual corneal transplantations in the Netherlands.

Corneal transplantation improves vision and quality of life in patients with corneal disease. Currently, the standard of care for patients with Fuchs Endothelial Corneal Dystrophy (FECD) is Descemet Stripping Automated Endothelial Keratoplasty (DSAEK), in which only the posterior layers of the cornea are transplanted. However, visual recovery following DSAEK is suboptimal. Descemet Membrane Endothelial Keratoplasty (DMEK), the latest technique in corneal transplantation involves transplantation of only a monolayer of corneal endothelium and Descemet's membrane providing the thinnest endothelial graft possible. DMEK has been suggested to result in faster and better visual recovery compared to DSAEK. While the economic burden, both medical and social, from this disease has not been assessed to date, costs associated with corneal transplantation reach $ 110 million dollars yearly for the 47.000 transplantations in the USA.

The objective of this project is to assess the effects and costs of DMEK vs. DSAEK in order to determine whether the new technique is effective and cost-effective over the standard technique.

The primary outcome measure is best-corrected visual acuity. Secondary outcome measures are contrast acuity, astigmatism, quality of vision, endothelial cell loss, incidence of graft rejection, primary graft failure, cornea donor loss due to preparation, and generic and vision-related quality of life.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
54
Inclusion Criteria
  • Cornea decompensation caused Fuchs Endothelial Corneal Dystrophy
Exclusion Criteria
  • Ocular comorbidities other than cataract
  • Previous corneal transplantation
  • Human leukocyte antigen (HLA) matched keratoplasty
  • Inability to complete follow-up

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
DMEKDMEKThe intervention group will receive cornea transplantation by DMEK
DSAEKDSAEKThe usual care / control group will receive cornea transplantation by DSAEK
Primary Outcome Measures
NameTimeMethod
Change in best-corrected visual acuityPreoperatively and 3, 6, 12 months post-operatively

Visual acuity will be measured by ETDRS letter charts

Secondary Outcome Measures
NameTimeMethod
Change in contrast sensitivityPreoperatively and 3, 6, 12 months post-operatively

Contrast sensitivity will be measured using the CSV-1000 chart by Vector Vision

Change in astigmatismPreoperatively and 3, 6, 12 months post-operatively

Astigmatism will be measured using the The Pentacam HR (Oculus Inc., Lynnwood, USA)

Change in corneal scatterPreoperatively and 3, 6, 12 months post-operatively

Corneal scatter will be measured using a confocal microscope

Change in endothelial cell lossPreoperatively and 3, 6, 12 months post-operatively

Endothelial cell loss will be measured using specular microscopy photography.

Incidence of graft rejection3, 6, 12 months post-operatively
Incidence of primary graft failure3, 6, 12 months post-operatively

Primary Graft failure will be assessed during ophthalmic examination.

Change in vision-related quality of lifePreoperatively and 3, 6, 12 months post-operatively

Vision-related quality of life will be measured using the National Eye Institute Visual Function Questionnaire (NEI VFQ-25), which is specified for vision-related quality of life.

Incidence of cornea donor loss due to preparationPreoperatively

The eye bank providing the donor cornea's will register cornea donor loss if a complication occurs during preparation that renders the cornea unusable.

Change in generic quality of lifePreoperatively and 3, 6, 12 months post-operatively

Generic quality of life will be measured using the EQ-5D-5L questionnaire, which tests 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression.

Trial Locations

Locations (1)

Maastricht University Medical Centre

🇳🇱

Maastricht, Limburg, Netherlands

© Copyright 2025. All Rights Reserved by MedPath